<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936168</url>
  </required_header>
  <id_info>
    <org_study_id>839-130312</org_study_id>
    <nct_id>NCT01936168</nct_id>
  </id_info>
  <brief_title>MOCA Versus RFA in the Treatment of Primary Great Saphenous Varicose Veins</brief_title>
  <acronym>MARADONA</acronym>
  <official_title>Mechanochemical Endovenous Ablation (MOCA) Versus RADiofrequeNcy Ablation (RFA) in the Treatment of Primary Great Saphenous Varicose Veins: a Multicentre Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The newly developed Mechanochemical Endovenous Ablation (MOCA) device uses a technique that
      combines mechanical endothelial damage using a rotating wire with the infusion of a liquid
      sclerosant. Heating of the vein and tumescent anesthesia are not required; only local
      anesthesia is utilized at the insertion site. Previously we showed that endovenous MOCA,
      using polidocanol, is feasible and safe in the treatment of great spahenous vein (GSV)
      incompetence. However, larger studies with a prolonged follow-up to prove the efficacy of
      this technique in terms of obliteration rates are lacking. This randomized trial was designed
      to compare occlusion rate, post-operative pain and complications between radiofrequency
      ablation (RFA: the current treatment for GSV incompetence) en MOCA.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occlusion rate</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Occlusion rates between treatments will be compared at mentioned time points (both technical and clinical success)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Per-procedural pain score</measure>
    <time_frame>two weeks</time_frame>
    <description>Pain during the procedure will be compared between treatments using the VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>30 days</time_frame>
    <description>Complication at day 30 will be compared between treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure duration</measure>
    <time_frame>30 days</time_frame>
    <description>The duration of the procedures will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of both treatments</measure>
    <time_frame>1 year</time_frame>
    <description>The total costs of both treatments will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>1 year, 5 years</time_frame>
    <description>Using the RAND 36-Item short From Health Survey (SF36) the general health status will be compared between treatments at various time points as specified by the protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post procedural pain score</measure>
    <time_frame>two weeks</time_frame>
    <description>Pain during the the first two weeks after the procedure will be compared between treatments using the VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease related quality of life</measure>
    <time_frame>1 year, 5 years</time_frame>
    <description>Using the Aberdeen Varicose Vein Questionnaire (AVVQ)the disease related quality of life will be compared between treatments at various time points as specified by the protocol.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recovery time</measure>
    <time_frame>30 days</time_frame>
    <description>Time until daily activities and or work can be resumed (measured in days)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Greater Saphenous Vein Injury</condition>
  <arm_group>
    <arm_group_label>RFA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiofrequency Ablation (RFA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanochemical Endovenous Ablation (MOCA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mechanochemical Endovenous Ablation (MOCA)</intervention_name>
    <description>Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence</description>
    <arm_group_label>MOCA</arm_group_label>
    <other_name>(MOCA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation (RFA)</intervention_name>
    <description>Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence</description>
    <arm_group_label>RFA</arm_group_label>
    <other_name>(RFA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Insufficiency of the GSV

          -  Signed informed consent

          -  Patient willing to participate in follow-up scheme

          -  Age &gt; 18 years

          -  Ultrasound criteria for endovenous treatment have been met:

          -  Diameter GSV between 3-12 mm

          -  No thrombus in the to be treated segment of the GSV

        Exclusion Criteria:

          -  Patient not able to give informed consent

          -  Patient unable to present at follow-up visits

          -  Other treatment is more suitable

          -  Pregnancy and breast feeding

          -  Known allergy/ contra-indication for sclerotherapy

          -  Previous ipsilateral surgical treatment of varicose veins

          -  Deep venous thrombosis or lung emboli in medical history

          -  Anticoagulant therapy

          -  C5-C6 varices

          -  Immobilization

          -  Fontaine II or IV peripheral arterial disease

          -  Severe kidney function decline (GFS &lt; 30 mL/min)

          -  Coagulation disorder or increased risk for thrombo-embolic complications(hemofilie A
             or B, v. Willebrand disease, Glanzmann disease, Factor VII-deficiency, idiopatic
             thrombocytopenic purpura, Factor V Leiden)

          -  Liver diseases accompanied by changes in blood coagulation, livver cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MMPJ Reijnen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital Arnhem</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BovenIJ Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCG</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Boersma D, van Eekeren RR, Werson DA, van der Waal RI, Reijnen MM, de Vries JP. Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein(Â®) device: one-year results of a prospective series. Eur J Vasc Endovasc Surg. 2013 Mar;45(3):299-303. doi: 10.1016/j.ejvs.2012.12.004. Epub 2013 Jan 9.</citation>
    <PMID>23312507</PMID>
  </reference>
  <reference>
    <citation>van Eekeren RR, Boersma D, Elias S, Holewijn S, Werson DA, de Vries JP, Reijnen MM. Endovenous mechanochemical ablation of great saphenous vein incompetence using the ClariVein device: a safety study. J Endovasc Ther. 2011 Jun;18(3):328-34. doi: 10.1583/11-3394.1.</citation>
    <PMID>21679070</PMID>
  </reference>
  <reference>
    <citation>van Eekeren RR, Boersma D, Konijn V, de Vries JP, Reijnen MM. Postoperative pain and early quality of life after radiofrequency ablation and mechanochemical endovenous ablation of incompetent great saphenous veins. J Vasc Surg. 2013 Feb;57(2):445-50. doi: 10.1016/j.jvs.2012.07.049. Epub 2012 Nov 8.</citation>
    <PMID>23141679</PMID>
  </reference>
  <reference>
    <citation>van Eekeren RR, Boersma D, de Vries JP, Reijnen MM. [Endovenous mechanochemical ablation for varicose veins--a new endovenous technique without tumescent anaesthesia]. Ned Tijdschr Geneeskd. 2011;155(33):A3177. Dutch.</citation>
    <PMID>21854655</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2013</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rijnstate Hospital</investigator_affiliation>
    <investigator_full_name>Michel Reijnen</investigator_full_name>
    <investigator_title>Surgeon</investigator_title>
  </responsible_party>
  <keyword>GSV</keyword>
  <keyword>Primary Varicose Veins</keyword>
  <keyword>Great Saphenous Vein</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

